Cargando…

Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study

BACKGROUND: Sodium-glucose cotransporter-2 inhibitors reduce blood pressure (BP) and renal and cardiovascular events in patients with type 2 diabetes through not fully elucidated mechanisms. Aim of this study was to investigate whether dapagliflozin is able to acutely modify systemic and renal vascu...

Descripción completa

Detalles Bibliográficos
Autores principales: Solini, Anna, Giannini, Livia, Seghieri, Marta, Vitolo, Edoardo, Taddei, Stefano, Ghiadoni, Lorenzo, Bruno, Rosa Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5654086/
https://www.ncbi.nlm.nih.gov/pubmed/29061124
http://dx.doi.org/10.1186/s12933-017-0621-8
_version_ 1783273341527785472
author Solini, Anna
Giannini, Livia
Seghieri, Marta
Vitolo, Edoardo
Taddei, Stefano
Ghiadoni, Lorenzo
Bruno, Rosa Maria
author_facet Solini, Anna
Giannini, Livia
Seghieri, Marta
Vitolo, Edoardo
Taddei, Stefano
Ghiadoni, Lorenzo
Bruno, Rosa Maria
author_sort Solini, Anna
collection PubMed
description BACKGROUND: Sodium-glucose cotransporter-2 inhibitors reduce blood pressure (BP) and renal and cardiovascular events in patients with type 2 diabetes through not fully elucidated mechanisms. Aim of this study was to investigate whether dapagliflozin is able to acutely modify systemic and renal vascular function, as well as putative mechanisms. METHODS: Neuro-hormonal and vascular variables, together with 24 h diuresis, urinary sodium, glucose, isoprostanes and free-water clearance were assessed before and after a 2-day treatment with dapagliflozin 10 mg QD in sixteen type 2 diabetic patients; data were compared with those obtained in ten patients treated with hydrochlorothiazide 12.5 mg QD. Brachial artery endothelium-dependent and independent vasodilation (by flow-mediated dilation) and pulse wave velocity were assessed. Renal resistive index was obtained at rest and after glyceryl trinitrate administration. Differences were analysed by repeated measures ANOVA, considering treatment as between factor and time as within factor; Bonferroni post hoc comparison test was also used. RESULTS: Dapagliflozin decreased systolic BP and induced an increase in 24 h diuresis to a similar extent of hydrochlorothiazide; 24 h urinary glucose and serum magnesium were also increased. 24 h urinary sodium and fasting blood glucose were unchanged. Oxidative stress was reduced, as by a decline in urinary isoprostanes. Flow-mediated dilation was significantly increased (2.8 ± 2.2 to 4.0 ± 2.1%, p < 0.05), and pulse-wave-velocity was reduced (10.1 ± 1.6 to 8.9 ± 1.6 m/s, p < 0.05), even after correction for mean BP. Renal resistive index was reduced (0.62 ± 0.04 to 0.59 ± 0.05, p < 0.05). These vascular modifications were not observed in hydrochlorothiazide-treated individuals. CONCLUSIONS: An acute treatment with dapagliflozin significantly improves systemic endothelial function, arterial stiffness and renal resistive index; this effect is independent of changes in BP and occurs in the presence of stable natriuresis, suggesting a fast, direct beneficial effect on the vasculature, possibly mediated by oxidative stress reduction.
format Online
Article
Text
id pubmed-5654086
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-56540862017-10-26 Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study Solini, Anna Giannini, Livia Seghieri, Marta Vitolo, Edoardo Taddei, Stefano Ghiadoni, Lorenzo Bruno, Rosa Maria Cardiovasc Diabetol Original Investigation BACKGROUND: Sodium-glucose cotransporter-2 inhibitors reduce blood pressure (BP) and renal and cardiovascular events in patients with type 2 diabetes through not fully elucidated mechanisms. Aim of this study was to investigate whether dapagliflozin is able to acutely modify systemic and renal vascular function, as well as putative mechanisms. METHODS: Neuro-hormonal and vascular variables, together with 24 h diuresis, urinary sodium, glucose, isoprostanes and free-water clearance were assessed before and after a 2-day treatment with dapagliflozin 10 mg QD in sixteen type 2 diabetic patients; data were compared with those obtained in ten patients treated with hydrochlorothiazide 12.5 mg QD. Brachial artery endothelium-dependent and independent vasodilation (by flow-mediated dilation) and pulse wave velocity were assessed. Renal resistive index was obtained at rest and after glyceryl trinitrate administration. Differences were analysed by repeated measures ANOVA, considering treatment as between factor and time as within factor; Bonferroni post hoc comparison test was also used. RESULTS: Dapagliflozin decreased systolic BP and induced an increase in 24 h diuresis to a similar extent of hydrochlorothiazide; 24 h urinary glucose and serum magnesium were also increased. 24 h urinary sodium and fasting blood glucose were unchanged. Oxidative stress was reduced, as by a decline in urinary isoprostanes. Flow-mediated dilation was significantly increased (2.8 ± 2.2 to 4.0 ± 2.1%, p < 0.05), and pulse-wave-velocity was reduced (10.1 ± 1.6 to 8.9 ± 1.6 m/s, p < 0.05), even after correction for mean BP. Renal resistive index was reduced (0.62 ± 0.04 to 0.59 ± 0.05, p < 0.05). These vascular modifications were not observed in hydrochlorothiazide-treated individuals. CONCLUSIONS: An acute treatment with dapagliflozin significantly improves systemic endothelial function, arterial stiffness and renal resistive index; this effect is independent of changes in BP and occurs in the presence of stable natriuresis, suggesting a fast, direct beneficial effect on the vasculature, possibly mediated by oxidative stress reduction. BioMed Central 2017-10-23 /pmc/articles/PMC5654086/ /pubmed/29061124 http://dx.doi.org/10.1186/s12933-017-0621-8 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Original Investigation
Solini, Anna
Giannini, Livia
Seghieri, Marta
Vitolo, Edoardo
Taddei, Stefano
Ghiadoni, Lorenzo
Bruno, Rosa Maria
Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study
title Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study
title_full Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study
title_fullStr Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study
title_full_unstemmed Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study
title_short Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study
title_sort dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5654086/
https://www.ncbi.nlm.nih.gov/pubmed/29061124
http://dx.doi.org/10.1186/s12933-017-0621-8
work_keys_str_mv AT solinianna dapagliflozinacutelyimprovesendothelialdysfunctionreducesaorticstiffnessandrenalresistiveindexintype2diabeticpatientsapilotstudy
AT gianninilivia dapagliflozinacutelyimprovesendothelialdysfunctionreducesaorticstiffnessandrenalresistiveindexintype2diabeticpatientsapilotstudy
AT seghierimarta dapagliflozinacutelyimprovesendothelialdysfunctionreducesaorticstiffnessandrenalresistiveindexintype2diabeticpatientsapilotstudy
AT vitoloedoardo dapagliflozinacutelyimprovesendothelialdysfunctionreducesaorticstiffnessandrenalresistiveindexintype2diabeticpatientsapilotstudy
AT taddeistefano dapagliflozinacutelyimprovesendothelialdysfunctionreducesaorticstiffnessandrenalresistiveindexintype2diabeticpatientsapilotstudy
AT ghiadonilorenzo dapagliflozinacutelyimprovesendothelialdysfunctionreducesaorticstiffnessandrenalresistiveindexintype2diabeticpatientsapilotstudy
AT brunorosamaria dapagliflozinacutelyimprovesendothelialdysfunctionreducesaorticstiffnessandrenalresistiveindexintype2diabeticpatientsapilotstudy